Scandonest L


Scandonest L

Drug - Scandonest L
The trade name of the product as shown on the labeling.

The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Levonordefrin; Mepivacaine Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - 0.05MG/ML;2%
The potency of the active ingredient(s), Levonordefrin; Mepivacaine Hydrochloride. May repeat for multiple part products.

Applicant - DEPROCO
The firm name holding legal responsibility for Scandonest L. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 088388
The FDA assigned number to Scandonest L. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Scandonest L. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AP
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Oct 10, 1984
The date Scandonest L was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Scandonest L. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Scandonest L is in. Format is RX, OTC, DISCN.

Applicant Full Name - Deproco Inc
The full name of the firm holding legal responsibility for the new application of Scandonest L.

Scandonest L